Phase II study of tight glycaemic control in COPD patients with exacerbations admitted to the acute medical unit

John R H Archer, Shivani Misra, Marcus Simmgen, Paul W Jones, Emma H Baker, John R H Archer, Shivani Misra, Marcus Simmgen, Paul W Jones, Emma H Baker

Abstract

Background: Hyperglycaemia is associated with poor outcomes from exacerbations of chronic obstructive pulmonary disease (COPD). Glycaemic control could improve outcomes by reducing infection, inflammation and myopathy. Most patients with COPD are managed on the acute medical unit (AMU) outside intensive care (ICU).

Objective: To determine the feasibility, safety and efficacy of tight glycaemic control in patients on an AMU.

Design: Prospective, non-randomised, phase II, single-arm study of tight glycaemic control in COPD patients with acute exacerbations and hyperglycaemia admitted to the AMU. Participants received intravenous, then subcutaneous, insulin to control blood glucose to 4.4-6.5 mmol/l. Tight glycaemic control was evaluated: feasibility, protocol adherence; acceptability, patient questionnaire; safety, frequency of hypoglycaemia (capillary blood glucose (CBG) <2.2 mmol/l and 2.2-3.3 mmol/l); efficacy, median CBG, fasting CBG, proportion of measurements/time in target range, glycaemic variability.

Results: were compared with 25 published ICU studies. Results 20 patients (10 females, age 71 ± 9 years; forced expiratory volume in 1 s: 41 ± 16% predicted) were recruited. Tight glycaemic control was feasible (78% CBG measurements and 89% of insulin-dose adjustments were adherent to protocol) and acceptable to patients. 0.2% CBG measurements were <2.2 mmol/l and 4.1% measurements 2.2-3.3 mmol/l. The study CBG and proportion of measurements/time in target range were similar to that of ICU studies, whereas the fasting CBG was lower, and the glycaemic variability was greater.

Conclusions: Tight glycaemic control is feasible and has similar safety and efficacy on AMU to ICU. However, as more recent ICU studies have shown no benefit and possible harm from tight glycaemic control, alternative strategies for blood glucose control in COPD exacerbations should now be explored. Trial registration number ISRCTN: 42412334. http://Clinical.Trials.gov NCT00764556.

Conflict of interest statement

Competing interests: None.

References

    1. Baker EH, Janaway CH, Philips BJ, et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 2006;61:284–9
    1. Chakrabarti B, Angus RM, Agarwal S, et al. Hyperglycaemia as a predictor of outcome during non invasive ventilation in decompensated COPD. Thorax 2009;64:857–62
    1. Louis M, Punjabi NM. Effects of acute intermittent hypoxia on glucose metabolism in awake healthy volunteers. J Appl Physiol 2009;106:1538–44
    1. Adrogué HJ, Chap Z, Okuda Y, et al. Acidosis-induced glucose intolerance is not prevented by adrenergic blockade. Am J Physiol 1988;255:E812–23
    1. Van Cromphaut SJ. Hyperglycaemia as part of the stress response: the underlying mechanisms. Best Pract Res Clin Anaesthesiol 2009;23:375–86
    1. Moretti M, Cilione C, Tampieri A, et al. Incidence and causes of non-invasive mechanical ventilation failure after initial success. Thorax 2000;55:819–25
    1. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002;106:2067–72
    1. Russell ST, Rajani S, Dhadda RS, et al. Mechanism of induction of muscle protein loss by hyperglycaemia. Exp Cell Res 2009;315:16–25
    1. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359–67
    1. Hemmila MR, Taddonio MA, Arbabi S, et al. Intensive insulin therapy is associated with reduced infectious complications in burn patients. Surgery 2008;144:629–37
    1. Hansen TK, Thiel S, Wouters PJ, et al. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 2003;88:1082–8
    1. Ellger B, Richir MC, van Leeuwen PA, et al. Glycemic control modulates arginine and asymmetrical-dimethylarginine levels during critical illness by preserving dimethylarginine-dimethylaminohydrolase activity. Endocrinology 2008;149:3148–57
    1. Biolo G, De Cicco M, Lorenzon S, et al. Treating hyperglycemia improves skeletal muscle protein metabolism in cancer patients after major surgery. Crit Care Med 2008;36:1768–75
    1. Griesdale DE, de Souza RJ, van Dam RM, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ 2009;180:821–7
    1. Cook CB, Castro JC, Schmidt RE, et al. Diabetes care in hospitalized noncritically ill patients: More evidence for clinical inertia and negative therapeutic momentum. J Hosp Med 2007;2:203–11
    1. Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009;32:1119–31
    1. Giangola J, Olohan K, Longo J, et al. Barriers to hyperglycemia control in hospitalized patients: a descriptive epidemiologic study. Endocr Pract 2008;14:813–19
    1. Vogelzang M, van der Horst IC, Nijsten MW. Hyperglycaemic index as a tool to assess glucose control: a retrospective study. Crit Care 2004;8:R122–7
    1. Eslami S, de Keizer NF, de Jonge E, et al. A systematic review on quality indicators for tight glycaemic control in critically ill patients: need for an unambiguous indicator reference subset. Crit Care 2008;12:R139.
    1. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449–61
    1. Finfer S, Chittock DR, Su SY, et al. ; NICE-SUGAR Study Investigators Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1346–9
    1. Pachler C, Plank J, Weinhandl H, et al. Tight glycaemic control by an automated algorithm with time-variant sampling in medical ICU patients. Intens Care Med 2008;34:1224–30
    1. Krinsley JS, Grover A. Severe hypoglycemia in critically ill patients: risk factors and outcomes. Crit Care Med 2007;35:2262–7
    1. Kanji S, Buffle J, Hutton B, et al. Reliability of point-of-care testing for glucose measurement in critically ill adults. Crit Care Med 2005;33:2778–85
    1. Hepburn DA, Patrick AW, Brash HM, et al. Hypoglycaemia unawareness in type 1 diabetes: a lower plasma glucose is required to stimulate sympatho-adrenal activation. Diabet Med 1991;8:934–45
    1. Whitmer RA, Karter AJ, Yaffe K, et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009;301:1565–72
    1. Bagshaw SM, Bellomo R, Jacka MJ, et al. The impact of early hypoglycemia and blood glucose variability on outcome in critical illness Crit Care 2009;13:R91.
    1. Monnier L, Colette C. Glycemic variability: should we and can we prevent it? Diabetes Care 2008;31(Suppl 2):S150–4
    1. Horváth EM, Benko R, Kiss L, et al. Rapid ‘glycaemic swings’ induce nitrosative stress, activate poly(ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus. Diabetologia 2009;52:952–61
    1. Pieracci F, Hydo L, Eachempati S, et al. Higher body mass index predicts need for insulin but not hyperglycemia, nosocomial infection, or death in critically ill surgical patients. Surg Infect (Larchmt) 2008;9:121–30
    1. Adair CG, McCallion O, McElnay JC, et al. A pharmacokinetic and pharmacodynamic comparison of plain and enteric-coated prednisolone tablets. Br J Clin Pharmacol 1992;33:495–9
    1. Martin RS, Smith JS, Hoth JJ, et al. Increased insulin requirements are associated with pneumonia after severe injury. J Trauma 2007;63:358–64

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren